Investigation of the Cytotoxic Effect of A New N-Phenyl Benzimidazole Derivative on Cell Viability in A549 and HepG2 Cell Lines

INTRODUCTION: One of the important heterocyclic compounds that exhibit versatile biological activity properties such as anti-inflammatory, antioxidant, and anti-proliferative/anticancer activities are benzimidazole-based compounds. In this study, a new benzimidazolium salt was synthesized. The cytotoxicity of this newly synthesized compound on HepG2 and A549 cell lines was investigated.
METHODS: In this study, a new benzimidazole salt was synthesized. Then, the cytotoxic effects of this compound (4) on human liver cell line (HepG2) and human lung cell line (A549) were investigated by MTT method.





RESULTS: Cellular proliferation was measured for both lung A549 and liver HepG2 cells. Lung and liver cells exposed to various concentrations of compound 4 and cisplatin were observed at the 72hour time point. Significant differences were detected in A549 cells treated with different concentrations of compound 4 and cisplatin (p=0.001<0.05). The doses that created the difference were found to be between 200μM and 25μM for compound 4 (p=0.017) and between 200μM and 50μM concentrations (p=0.001). There were also significant differences between doses for cisplatin (p=0.001<0.05). There is a difference between compound 4 and cisplatin (p<0.05). In the treatment of HepG2 cells with different doses of compound 4 and cisplatin, significant differences were detected between compound 4 and cisplatin (p=0.035<0.05).
DISCUSSION AND CONCLUSION: Benzimidazole derivatives have various biological activities, including antitumor activity. We tested this compound against two different human cancer cell lines including lung and liver. The results show that compound 4 had cytotoxic effects on both A549 and HepG2.